_edited.png)
Key Player In The Vial Rubber Stopper Market
These top 4 companies account for 70% of the global pharmaceutical vial rubber stopper market. Our innovative and highly differentiated vial cap will be comparably priced to products currently on the market providing Klim-Loc with a clear competitive advantage.
OUR MISSION
Key player in the vial rubber stopper market
These top 4 companies account for 70% of the global pharmaceutical vial rubber stopper market. Our innovative and highly differentiated vial cap will be comparably priced to products currently on the market providing Klim-Loc with a clear competitive advantage.
_edited.png)
The problem
Needlestick injuries in the healthcare industry
45% of healthcare workers experience at least one needlestick injury (nsi) per year. The problem is so pervasive that Congress enacted the Needlestick Safety and Prevention Act in 2000. Yet, despite the scale and urgency of the risk, meaningful innovation to address this widespread problem has been limited.
Evade
Treg cells block other immune cells from attacking cancer cells.
.png)
The Solution
Redesign the pharmaceutical vial cap.
Our revolutionary needleless technology provides a smarter, safer, and more efficient system for extraction and delivery of pharmaceuticals and IV fluids expediently and seamlessly to patients.
Attack
SRC-3 KO Treg cells permit effector immune cells to attack and kill cancer cells.
We are disrupting this entire multi-billion dollar market.
Go-to-Market Strategy
Steps I & II
Klim-Loc’s revolutionary technology streamlines medication improving safety, speed, and efficiency across all healthcare settings. Universally applicable and highly scalable, Klim-Loc is positioned to capture significant market share through strategic partnerships and licensing, becoming the global standard in medicine delivery.
FUTURE
Future Product Expansion
A pipeline of revolutionary, sensor-integrated products designed to work synergistically, expanding impact, efficiency, and value, across healthcare applications.
Spikeless & Needleless IV
Fluid Bag & Infusion Set
Eliminates the need to 'spike' IV fluid bags by replacing the spike port with a patented threaded port system for seamless infusion set coupling.
IV bag threaded accessory port provides a needleless site to extract IV fluid and to inject medications with a Luer-Lock syringe.
Innovative, efficient, and safe.
patent filed &
working prototype
Sensor Technology
Real-time data collection of pharmaceutical and fluid administration.
Auto populates data into EMR: time stamp, personnel administering, medication administered, volume & dose, lot#, expiration date, usage rate, and more.
Relieves charting, administrative, logistical, and supply chain burdens.
The Benefits
T memory cell population is increased in animals treated with engineered SRC-3 KO Treg cells
Smaller number of engineered SRC-3 KO Treg cellsdominate over existing normal Treg cells within tumor tissue
SRC-3 KO Treg cells attract CD8+, CD4+ and NK tumor killing effector cells into tumors
.png)
Because Safety
Shouldn't Be an Upgrade.
Healthcare has evolved dramatically. Patient safety has improved. Digital health has transformed workflows. Yet millions of clinicians still rely on processes that expose them to unnecessary risk. KLIM-LOC was created to change that.
The Current Solution - Complexity and Cost of Adoptive Cell Transfer
Genetically altering cells to treat disease often requires adoptive cell transfer, a process that is proven to be effective but can be complex and resource-intensive.
Our Approach - A ‘Therapy in a Bottle’
We are developing an injectable biologic capable of genetic engineering directly in the body, eliminating the need for external cell manipulation. This innovation enables treatment anywhere IV access is available, making advanced therapies more accessible.
Disruptive Technology with Far-Reaching Potential
This approach has the potential to replace most adoptive cell therapies, offering a simpler, more scalable alternative for genetic treatments.
Expanding the Possibilities of Gene Engineering
Our technology leverages an in vivo, cell- and tissue-directed Cas9 fusion protein, which can be paired with:
-
Any cell-targeting antibody to reach specific cell types
-
Any sgRNA to edit any of the ~20,000 human genes